Table 1.

Analysis of exogenous erythropoietin administration and locoregional progression-free survival by mRNA marker status^a

mRNA Marker/Resection Stratum	Below Medianb Marker Value			Above Medianb Marker Value
	Number of Patients		Log Rank p Valuec	Number of Patients		Log Rank p Valuec
	Epo	Placebo		Epo	Placebo
EpoR
All patients	24	27	0.22	23	27	0.31
Complete	11	13	0.90	14	10	0.47
Incomplete	5	8	0.17	6	6	0.82
No resection	7	7	0.80	4d	10d	0.02d
Jak2
All patients	29	29	0.65	26	31	0.15
Complete	14	14	0.12	14	13	0.15
Incomplete	7	6	0.33	4	8	0.71
No resection	8	10	0.34	8d	9d	0.04d
Hsp70e
All Patients	31	31	0.98	29	32	0.40
Complete	15	15	0.26	15	14	0.74
Incomplete	6	7	0.79	5	7	0.16
No resection	9d	11d	0.01d	10	9	0.38
Csf2rb
All patients	24	29	0.55	26	27	0.83
Complete	9	17	0.57	17	8	0.34
Incomplete	5	8	0.78	6	6	0.18
No resection	9	6	0.35	4	11	0.26
Cd44
All Patients	30	32	0.73	30	31	0.50
Complete	16	14	0.70	14	15	0.96
Incomplete	5	8	0.52	6	6	0.89
No resection	9	11	0.12	10	9	0.10
Krt5
All Patients	30	27	0.84	27	30	0.28
Complete	17	10	0.86	10	16	0.61
Incomplete	4	9	0.89	7	5	0.65
No resection	10	8	0.26	9	9	0.08

^aStratification was above versus below/equal to the median.

^bThe median was calculated separately for all patients and within each resection stratum.

^cThe p value is two sided and is based on the log rank test to compare differences in Kaplan Meier distributions in response to Epo versus placebo.

^dGroups with significant adverse effects of Epo.

^eHsp70 mRNA represents the cumulative expression of all 8 family members. Results for individual family members are presented in Supporting information Table 4.